STOCK TITAN

Nasdaq warns Cypherpunk (CYPH) after shares stay below $1 minimum bid

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).

The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.

Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.

Positive

  • None.

Negative

  • Nasdaq minimum bid-price noncompliance and delisting risk: Cypherpunk’s stock has stayed below the $1.00 minimum bid for 30 consecutive business days, starting a 180-day cure period with only conditional prospects for an extension and no assurance of regaining compliance.

Insights

Nasdaq bid-price noncompliance introduces real delisting risk for Cypherpunk.

Cypherpunk Technologies Inc. has fallen below Nasdaq’s $1.00 minimum bid requirement for 30 consecutive business days. This triggers a formal deficiency period but not an immediate delisting, so the shares continue to trade on the Nasdaq Capital Market for now.

The company has until August 31, 2026 to achieve at least $1.00 closing bid for 10 consecutive business days. Nasdaq may grant an extra 180 days if other initial listing criteria, like market value of publicly held shares, are satisfied and Cypherpunk commits in writing to cure the deficiency.

Management notes it may consider actions including a reverse stock split, which can mechanically lift the share price but does not change underlying value. Actual outcomes will depend on share price performance and any corporate actions disclosed in future periodic or current reports.

false 0001509745 0001509745 2026-03-04 2026-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 4, 2026

 

 

 

Cypherpunk Technologies Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37990   27-4412575
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

47 Thorndike Street, Suite B1-1
Cambridge, MA
02141
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (617714-0360

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 CYPH Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 3.01  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On March 4, 2026, Cypherpunk Technologies Inc. (the “Company”) received a notification letter (the “Closing Bid Price Deficiency Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Closing Bid Price Deficiency Letter is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the Company’s shares of common stock on The Nasdaq Capital Market.

 

The Company has 180 days, or until August 31, 2026, to regain compliance with Rule 5550(a)(2) by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Additionally, the Company may be eligible for an additional compliance period of 180 calendar days if, on August 31, 2026, the Company meets the continued listing requirement for market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital Market (with the exception of the closing bid price requirement) based on the Company’s then most recent public filings and market information, and the Company provides written notice to Nasdaq of its intent to cure during such additional compliance period of 180 calendar days the deficiency in the Company’s compliance with the minimum closing bid price requirement of Rule 5550(a)(2), including, without limitation, by effecting a reverse stock split, if necessary.

 

The Company intends to monitor closely the closing bid price of its common stock and to consider plans for regaining compliance with Rule 5550(a)(2). While the Company plans to review all available options, there can be no assurance that it will be able to regain compliance with the applicable rules during the 180-day compliance period ending on August 31, 2026, any additional compliance period, or at all.

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYPHERPUNK TECHNOLOGIES INC.
   
   
Dated: March 9, 2026 By: /s/ Douglas E. Onsi
  Name: Douglas E. Onsi
  Title: Chief Executive Officer and President

 

 

Filing Exhibits & Attachments

3 documents
Leap Therapeutic

NASDAQ:LPTX

View LPTX Stock Overview

LPTX Rankings

LPTX Latest News

LPTX Latest SEC Filings

LPTX Stock Data

116.14M
49.89M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE